References
- Patton JS . The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc.1, 338–344 (2004).
- Ashish AK . Pulmonary drug delivery system. Int. J. Pharm. Tech. Res.4(1), 293–305 (2012).
- Labiris NR . Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol.56(6), 588–599 (2003).
- Frijlink HW . Dry-powder inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv.1(1), 67–86 (2004).
- Pfutzner A . Technosphere/insulin – a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol. Ther.4(5), 589–594 (2002).
- Donovan MJ . Dry-powder inhaler device influence on carrier particle performance. J. Pharm. Sci.101(3), 1097–1107 (2012).
- de Boer AH . Air classifier technology (ACT) in dry powder inhalation part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int. J. Pharm.260, 187–200 (2003).
- Telko MJ . Dry-powder inhaler formulation. Respir. Care50(9), 1209–1227 (2005).
- Geller DE . Development of an inhaled dry-powder formulation of tobramycin using pulmosphere technology. J. Aersol Med. Pulm. Drug Deliv.24(4), 175–182 (2011).
- Koushik K . Particle & device engineering for inhalation drug delivery. Drug Develop. Deliv.4(2), 2–5 (2004).
- Chow AH , TongHH, ChattopadhyayP, ShekunovBY. Particle engineering for pulmonary drug delivery. Pharm. Res.24(3), 411–437 (2007).
- Mitchell J . In vitro and in vivo aspects of cascade impactor tests and inhaler perfomance: a review. AAPS PharmSciTech8(4), 237–248 (2007).
- Mitchell JP . Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. J. Aerosol Med.19(4), 409–433 (2006).
- de Boer AH . Inhalation characteristics and their effects on in vitro drug delivery from Dry-powder inhalers part 1. Inhalation characteristics, work of breathing and volunteers‘ preference in dependence of the inhalers resistance. Int. J. Pharm.130, 231–244 (1996).
- Smutney CC . Inspiratory efforts achieved in use of the technosphere insulin inhalation system. J. Diabetes Sci. Technol.3(5), 1175–1182 (2009).
- Usmani OS . Regional lung deposition and bronchodialator response as a function of β2-agonist particle size. Am. J. Respir. Crit. Care Med.172(12), 1497–1504 (2005).
- Svartengren K . Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am. J. Respir. Crit. Care Med.152(1), 32–37 (1995).
Websites
- Weiner BB. What is particle size distribution weighting: how to get fooled about what was measured and what it means? (2011). www.brookhaveninstruments.com/pdf/What_is_Particle_Size.pdf
- de Koning JP. Dry powder inhalation: technical and physiological aspects, prescribing and use. Dissertation, University of Groningen. http://dissertations.ub.rug.nl/faculties/science/2001/j.p.de.koning/
- Al Habet S. NDA Application 21–868 Exubera Inhaled Insulin. Center For Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review Final, 52–54. www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021868s000_ClinPharmR.pdf
- Hovione. Dry powder inhalation devices. TwinCaps. www.hovione.com/inhalation/TwinCaps.pdf